Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorder, Childhood Developmental Disorders, Pervasive
Interventions: Sulforaphane, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years to 30 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Carrboro, North Carolina

Conditions: Primary Biliary Cholangitis
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 10
States / cities: Coronado, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Episodic Migraine
Interventions: Atogepant, Placebo-Matching Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 42
States / cities: Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more

Conditions: Healthy
Interventions: PF-04171327, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: BEKINDA, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more

Conditions: Glioblastoma
Interventions: Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 230
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more

Conditions: Vaping, E-Cig Use
Interventions: cytisinicline, Placebo, Behavioral support; Drug · Behavioral
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Lexington, Kentucky • Boston, Massachusetts • Rochester, New York + 2 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 42
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 37 more

Conditions: Rheumatoid Arthritis
Interventions: ATI-450 50 mg oral tablet BID, Placebo oral tablet, Methotrexate, ATI-450 20 mg oral tablet BID; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: El Cajon, California • Encino, California • La Jolla, California + 8 more

Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
Interventions: Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule; Drug
Lead sponsor: Institute for Asthma and Allergy; Network
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Hepatitis C, Medication Adherence
Interventions: AiCure, AiCure with gamification; Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Substance Use
Interventions: Standard Screening, Standard Psychoeducation, Standard Brief Negotiated Interview (BNI), Standard Referral to Treatment (RT), Family Screening, Family Psychoeducation, Family Brief Negotiated Interview (BNI), Family Facilitated Conversation (FC) & Referral to Treatment (RT); Behavioral
Lead sponsor: The National Center on Addiction and Substance Abuse at Columbia University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Embryo Transfer
Interventions: Epelsiban; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Immunosuppressant Regimen; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Hepatitis C, HIV-1-infection, Liver Diseases
Interventions: Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy; Drug · Other
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: Constipation Drug Induced
Interventions: Methylnaltrexone Bromide 150 mg Oral Tablet, Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1, Naloxegol 25 MG Oral Tablet; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions: Buprenorphine/naloxone, Placebo Oral Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Repaglinide, Pirtobrutinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 1,394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more

Conditions: Partial Epilepsy
Interventions: 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 106
States / cities: Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more

Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions: Olaparib, Physician's choice chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 42
States / cities: San Diego, California • Santa Rosa, California • Whittier, California + 35 more

Conditions: Cardiovascular Disease, Interventional Cardiology
Interventions: Aspirin, Placebo, ticagrelor; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Sub-acute Back Pain
Interventions: Naproxen, Carbidopa/Levodopa, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Study of Cytisinicline for Vaping Cessation in Adult Smokers

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs

Primary Connections for Youth and Families

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

HIV, Buprenorphine, and the Criminal Justice System

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Effect of L-dopa In Subacute Back Pain Population